A Phase 2 interventional study of 0.5% Roflumilast Cream and Vehicle Cream in Atopic Dermatitis, sponsored by AstraZeneca. Completed at 3 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-01.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.
Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Integrative Skin Science and Research · Sites in United States
Ages 12+
Nora Mohamed Abdelrazik · Sites in Egypt
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 136 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 6 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
1 of the studies testing roflumilast in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07560618Integrative Skin Science and ResearchObtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing roflumilast in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of topical roflumilast on the reduction of atopic dermatitis lesions in adults with atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
Drug: 0.5% Roflumilast Cream
Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
Drug: Vehicle Cream
Roflumilast 0.5% cream
Roflumilast formulation vehicle
Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)
Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.
Time frame: Baseline and Day 15
Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values
Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.
Time frame: Baseline and Day 15
Change From Baseline to Day 15 in Participants' Assessment of Pruritus
Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.
Time frame: Baseline and Day 15
Participants took part in the study at 3 centers in Germany from 10 June 2013 to 18 March 2014.
| Milestone | 0.5% Roflumilast Cream | Vehicle Cream |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 20 |
| Not completed | 0 | 0 |
Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.
| Scores on a scale | 0.5% Roflumilast Cream | Vehicle Cream |
|---|---|---|
| Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) | -2.30 ± 0.354 | -1.75 ± 0.347 |
Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.
| g/m^2/hr | 0.5% Roflumilast Cream | Vehicle Cream |
|---|---|---|
| Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values | -18.60 ± 2.467 | -12.69 ± 2.417 |
Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.
| Scores on a scale | 0.5% Roflumilast Cream | Vehicle Cream |
|---|---|---|
| Change From Baseline to Day 15 in Participants' Assessment of Pruritus | -3.05 ± 0.426 | -1.50 ± 0.417 |
Collected over From the time informed consent is signed through 7 days after the last dose of study drug (up to Day 22). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5% Roflumilast Cream | — | 0/20 (0%) | 5/20 (25%) |
| Vehicle Cream | — | 0/20 (0%) | 3/20 (15%) |
| Event | 0.5% Roflumilast Cream | Vehicle Cream |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/20 | 0/20 |
| Application Site PainGeneral disorders | 1/20 | 1/20 |
| Gamma-glutamyltransferase increasedInvestigations | 1/20 | 0/20 |
| Alanine aminotransferase increasedInvestigations | 1/20 | 0/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/20 | 0/20 |
| Red blood cells urineInvestigations | 0/20 | 1/20 |
| Blood creatine phosphokinase increasedInvestigations | 0/20 | 1/20 |
Full Analysis Set
| Age, Continuous(Years) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 32.7 ± 11.50 | 36.5 ± 9.65 | 34.6 ± 10.66 |
| Gender(Participants) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Female | 9 | 11 | 20 |
| Male | 11 | 9 | 20 |
| Race (NIH/OMB)(Participants) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 20 | 20 | 40 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Germany | 20 | 20 | 40 |
| Height(centimeters) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 177.3 ± 9.27 | 174.9 ± 10.13 | 176.1 ± 9.66 |
| Weight(kilograms) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 81.72 ± 21.757 | 78.31 ± 12.965 | 80.02 ± 17.762 |
| Body Mass Index (BMI)(kg/m^2) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 25.65 ± 5.007 | 25.59 ± 3.477 | 25.62 ± 4.255 |
| Smoking Classificaiton(participants) | 0.5% Roflumilast Cream | Vehicle Cream | Total |
|---|---|---|---|
| Never smoked | 5 | 8 | 13 |
| Current smoker | 10 | 9 | 19 |
| Ex-Smoker | 5 | 3 | 8 |
4 further baseline measures are reported on the registry.
The record gives a start of Jun 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast